Company / R&D per Share
Moderna R&D per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$8.11
FY2025
5-year range
$1.24 / $12.58
FY2021-FY2025
Trend
-31.8%
vs FY2024
Sector context
#21 of 208
Health Care
What the data says
Among 208 Health Care companies, Moderna is in the top 10% for r&d per share. R&D per Share has fluctuated over the past 10 years, ranging from $1.24 in FY2021 to $12.58 in FY2023.
Based on SEC 10-K filings.
8.11 in FY2025 with a 5-year CAGR of +14.8%. Top quartile in the Health Care sector.
Declined from $12.58 to $8.11 over the past 2 years.
Health Care sector context is included.
R&D per Share over time
Growth rates
- 3-Year CAGR
- +33.6%
- 5-Year CAGR
- +14.8%
- 10-Year CAGR
- -
Sector benchmark
Top 10% in Health CareTop 10% of 208This company $8.11 Sector average $28.82
▼
-71.8% below sector average
Key checks
Key Insights
- In FY2025, r&d per share decreased 31.8% year-over-year.
- Ranks #21 out of 208 companies in the Health Care sector.
- Peak r&d per share was recorded in FY2023.
- Lowest r&d per share in the period was in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 1.13 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $8.11 | -31.8% |
| FY2024 | $11.89 | -5.5% |
| FY2023 | $12.58 | +270.2% |
| FY2022 | $3.40 | +173.5% |
| FY2021 | $1.24 | -69.5% |
| FY2020 | $4.07 | +169.9% |
| FY2019 | $1.51 | -78.3% |
| FY2018 | $6.96 | +9.4% |
| FY2017 | $6.36 | +40.7% |
| FY2016 | $4.52 | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026